Glenmark Life Sciences IPO Day 1: Should you subscribe?

Date:

Today is the first day of Glenmark Life Sciences’ first public offering (IPO).

The initial public offering (IPO) of Glenmark Life Sciences was launched today and received a significant reaction from participants, with the issue subscribed in less than two hours. Retail investors have oversubscribed the issuance.

The Rs 1,541 crore public offering contains a mixture of new equities and an offer for sale (OFS) from current shareholders. Glenmark Life Sciences started trading at a low premium in the grey market on the first day of the bid.

Retail investors subscribed to the issue 2.46 times. The public offering drew a positive response from retail investors, who subscribed to their quotas within the first hour.

The issue has ben subscribed 0.21 times by non-institutional buyers. In the meantime, Qualified Institutional Buyers (QIB) are yet to make a significant offer for the issue.

QIBs will get 50% of the IPO, retail investors will get 35%, and NIIs will get 15%. The transaction was oversubscribed 1.28 times, with investors vying for 2.02 crore equity shares out of a total of 1.5 crores available. 

Glenmark Life Sciences was dealing in the unregistered category for Rs 125-150 per share. Glenmark Life Sciences sold at a premium of Rs 135 per share on the grey market before the IPO.

Should you get a subscription?

As part of the OFS, the business would get Rs 1,060 from the issuance, remaining the selling shareholders. Glenmark intends to pay off the acquisition price for the company.

Glenmark Life Sciences has a clean legal record, with no violation notices or trade warnings from regulatory bodies.

Analysts at ICICI Direct think the issue is valued at FY21 EV/EBITDA of 14.7x on the top end of the pricing band. The stock gets a subscription rating from ICICI Direct.

Glenmark Life Sciences, a Glenmark Pharmaceuticals division, is a prominent researcher and producer of non-commoditized active pharmaceutical ingredients (APIs) in critical medical specialities such as heart disease, nervous system illness, pain control, and diabetes.

APIs for gastrointestinal diseases, anti-infectives, and other medical fields are also manufactured and sold by the firm.

S N NIMISHA
S N NIMISHA
A passionate writer who loves to juggle words and create impressive and thoughtful passages. An aspiring content/ copywriter who is willing to take any amount of hard work to achieve her goals in life. Responsible for providing original and reliable content to the audience. Tries the best in creating engaging content for any topic. Believes that any writing can be made perfect with the right usage of grammar and punctuation. Always having the zest to give the best output possible. Always accountable for her mistakes and is open to constructive criticisms. An explorer of the self and the world; Always a learner!

Subscribe

Popular

More like this
Related

Following the court order, the CRPF took possession of the Gyanvapi Mosque premises in Varanasi

The CRPF was deployed at the Gyanvapi Mosque premises...

SC commutes the death penalty for rape convicts

The Supreme Court remitted the death penalty of a man accused of raping and murdering a juvenile to life in prison, considering the possibility and likelihood of the defendant's reformation and rehabilitation. The obvious and indisputable fact that the appellant had no criminal histories and comes from a poor socioeconomic background, as well as his pristine conduct inside the jail, cannot go ignored," the Supreme Court concluded. Ins conclusion, Supreme Court said that the...

International Museum day celebrating young educators

International Museum Day, a five day long programme of...

Met Gala and its implications

By: Akshinta Das Introduction The Met Gala is fashion's big night out --...